Frankfurt - Delayed Quote EUR

Repligen Corporation (RGN.F)

110.00

-1.15

(-1.03%)

As of 8:09:48 AM GMT+2. Market Open.

Repligen to Report First Quarter 2025 Financial Results

Webcast and Conference Call to Be Held Tuesday, April 29, 2025, at 8:30 a.m. ETWALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2025 financial results on Tuesday, April 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2025.

GlobeNewswire 23 hours ago

RGEN
Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings?

Repligen trades at $120.32 per share and has moved almost in lockstep with the market over the last six months. The stock has lost 10.5% while the S&P 500 is down 7.7%. This might have investors contemplating their next move.

StockStory 6 days ago

RGEN
Repligen Appoints Jacob Johnson As Vice President Investor Relations

WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team’s engagement with the investment community, reporting to the company’s Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing Director, Research Analyst at Stephens Inc., where he followed the life sciences tools and pharma serv

GlobeNewswire 7 days ago

RGEN
Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?

Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 8 days ago

RGEN

ZEAL.CO
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest of the drug development inputs & services stocks fared in Q4.

StockStory 21 days ago

IQV

UFPT

RGEN
Is Repligen Corporation (RGEN) the Top Stock to Buy According to 12 West Capital Management?

We recently published a list of Top 10 Stocks to Buy According to 12 West Capital Management. In this article, we are going to take a look at where Repligen Corporation (NASDAQ:RGEN) stands against other top stocks to buy according to 12 West Capital Management. Joel Ramin founded 12 West Capital Management in August 2011, establishing it […]

Insider Monkey 21 days ago

RGEN
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers.

StockStory 26 days ago

CRL

RGEN
Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?

Ascendis Pharma (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks 28 days ago

ASND

RGEN
Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers.

StockStory 30 days ago

TECH

RGEN

PACB
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Azenta (NASDAQ:AZTA) and its peers.

StockStory last month

UFPT

RGEN
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and its peers.

StockStory last month

RGEN
3 Small-Cap Stocks Skating on Thin Ice

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

StockStory last month

RGEN

ICUI
Q4 2024 908 Devices Inc. Earnings Call

Q4 2024 908 Devices Inc. Earnings Call

Thomson Reuters StreetEvents last month

MASS

RGEN
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

On Tuesday, Repligen Corporation (NASDAQ:RGEN) purchased 908 Devices Inc.’s (NASDAQ:MASS) desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. The purchase consideration is a payment of $70 million in cash. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for health and safety applications. Adding these desktop assets complements and strengthens Repligen’s differentiated PAT portfolio, providing its biophar

Benzinga last month

MASS

RGEN
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

Portfolio includes PAT devices for real-time process monitoring, control and analysisWALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices’ desktop portfolio of four devices for bioprocessing process analytical technol

GlobeNewswire last month

RGEN

MASS
Repligen's Q4 Earnings Beat Estimates, Revenues In Line

RGEN reports decent fourth-quarter results and issues guidance for 2025.

Zacks last month

RGEN
Repligen Corp (RGEN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Repligen Corp (RGEN) reports robust fourth-quarter revenue growth, driven by product differentiation and strategic initiatives, while setting optimistic guidance for 2025.

GuruFocus.com last month

RGEN
Q4 2024 Repligen Corp Earnings Call

Q4 2024 Repligen Corp Earnings Call

Thomson Reuters StreetEvents last month

RGEN
Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

Repligen Corp (NASDAQ:RGEN) released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago but beating the consensus of 41 cents. The bioprocessing technology reported sales of $167.55 million, slightly up from $166.6 million a year ago, almost in line with the consensus of $167.67 million. Olivier Loeillot, President and Chief Executive Officer of Repligen, said, "During the fourth quarter, we were very encouraged by the continued momentum across our portfolio. T

Benzinga last month

RGEN
February 2025's US Stocks That May Be Trading Below Fair Value

As the U.S. stock market experiences a period of record highs for major indices like the S&P 500, investors are keenly observing fluctuations in stock futures and economic indicators such as Treasury yields and Federal Reserve policies. In this context, identifying stocks that may be trading below their fair value can offer potential opportunities, especially when considering factors like earnings performance and broader market trends.

Simply Wall St. last month

ONB

ONBPO

RGEN

Performance Overview

Return	RGN.F	S&P 500 (^GSPC)
YTD	-20.12%	-8.25%
1-Year	-29.03%	+6.83%
3-Year	-23.30%	+22.86%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Repligen Corporation (RGN.F)

Repligen to Report First Quarter 2025 Financial Results

Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings?

Repligen Appoints Jacob Johnson As Vice President Investor Relations

Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?

Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

Is Repligen Corporation (RGEN) the Top Stock to Buy According to 12 West Capital Management?

Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers

Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?

Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks

Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks

A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

3 Small-Cap Stocks Skating on Thin Ice

Q4 2024 908 Devices Inc. Earnings Call

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

Repligen's Q4 Earnings Beat Estimates, Revenues In Line

Repligen Corp (RGEN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Q4 2024 Repligen Corp Earnings Call

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

February 2025's US Stocks That May Be Trading Below Fair Value

Performance Overview